Cintia E. Citterio

Dr. Cintia E. Citterio

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2019 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
CCCintia E. Citterio
Cintia E. Citterio
HTHéctor M. Targovnik
Héctor M. Targovnik
PAPeter Arvan
Peter Arvan

7 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWei Zhou
Wei Zhou
BBBen Brumpton
Ben Brumpton
OKOmer Kabil
Omer Kabil
JGJulius Gudmundsson
Julius Gudmundsson
GTGudmar Thorleifsson
Gudmar Thorleifsson
BÅBjørn Olav Åsvold
Bjørn Olav Åsvold
Thyroid stimulating hormone (TSH) is critical for normal development and metabolism. To better understand the genetic contribution to TSH levels, we conduct a GWAS meta-analysis at 22.4 million genetic markers in up to 119,715 individuals and identify 74 genome-wide significant loci for TSH, of which 28 are previously unreported. Functional experiments show that the thyroglobulin protein-altering variants P118L and G67S impact thyroglobulin secretion. Phenome-wide association analysis in the UK Biobank demonstrates the pleiotropic effects of TSH-associated variants and a polygenic score for higher TSH levels is associated with a reduced risk of thyroid cancer in the UK Biobank and three other independent studies. Two-sample Mendelian randomization using TSH index variants as instrumental variables suggests a protective effect of higher TSH levels (indicating lower thyroid function) on risk of thyroid cancer and goiter. Our findings highlight the pleiotropic effects of TSH-associated variants on thyroid function and growth of malignant and benign thyroid tumors.

1 March 2017 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
HTHéctor Targovnik
Héctor Targovnik
CCCintia E. Citterio
Cintia E. Citterio
CRCarina M. Rivolta
Carina M. Rivolta

3 March 2011 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
HTHéctor Targovnik
Héctor Targovnik
CCCintia E. Citterio
Cintia E. Citterio
CRCarina M. Rivolta
Carina M. Rivolta
Human thyroglobulin (TG) gene is a single copy gene, 270 kb long, that maps on chromosome 8q24.2–8q24.3 and contains an 8.5-kb coding sequence divided into 48 exons. TG is exclusively synthesized in the thyroid gland and represents a highly specialized homodimeric glycoprotein for thyroid hormone biosynthesis. Mutations in the TG gene lead to permanent congenital hypothyroidism. The presence of low TG level and also normal perchlorate discharge test in a goitrous individual suggest a TG gene defect. Until now, 52 mutations have been identified and characterized in the human TG gene with functional impact such as structural changes in the protein that alter the normal protein folding, assembly and biosynthesis of thyroid hormones. 11 of the mutations affect splicing sites, 11 produce premature stop codons, 23 lead to amino acid changes, 6 deletions (5 single and 1 involving a large number of nucleotides) and 1 single nucleotide insertion. TG mutations are inherited in an autosomal recessive manner and affected individuals are either homozygous or compound heterozygous. The p.R277X, p.C1058R, p.C1977S, p.R1511X, p.A2215D and p.R2223H mutations are the most frequently identified TG mutations. This mini-review focuses on genetic and clinical aspects of TG gene defects.

1 September 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CCCintia E. Citterio
Cintia E. Citterio
BVBalaji Veluswamy
Balaji Veluswamy
SMSarah J. Morgan
Sarah J. Morgan
VGValerie A. Galton
Valerie A. Galton
JBJ. Paul Banga
J. Paul Banga
PAPeter Arvan
Peter Arvan
The thyroid gland secretes primarily tetraiodothyronine (T4), and some triiodothyronine (T3). Under normal physiological circumstances, only one-fifth of circulating T3 is directly released by the thyroid, but in states of hyperactivation of thyroid-stimulating hormone receptors (TSHRs), patients develop a syndrome of relative T3 toxicosis. Thyroidal T4 production results from iodination of thyroglobulin (TG) at residues Tyr5 and Tyr130, whereas thyroidal T3 production may originate in several different ways. In this study, the data demonstrate that within the carboxyl-terminal portion of mouse TG, T3 is formed de novo independently of deiodination from T4. We found that upon iodination in vitro, de novo T3 formation in TG was decreased in mice lacking TSHRs. Conversely, de novo T3 that can be formed upon iodination of TG secreted from PCCL3 (rat thyrocyte) cells was augmented from cells previously exposed to increased TSH, a TSHR agonist, a cAMP analog, or a TSHR-stimulating antibody. We present data suggesting that TSH-stimulated TG phosphorylation contributes to enhanced de novo T3 formation. These effects were reversed within a few days after removal of the hyperstimulating conditions. Indeed, direct exposure of PCCL3 cells to human serum from two patients with Graves' disease, but not control sera, led to secretion of TG with an increased intrinsic ability to form T3 upon in vitro iodination. Furthermore, TG secreted from human thyrocyte cultures hyperstimulated with TSH also showed an increased intrinsic ability to form T3. Our data support the hypothesis that TG processing in the secretory pathway of TSHR-hyperstimulated thyrocytes alters the structure of the iodination substrate in a way that enhances de novo T3 formation, contributing to the relative T3 toxicosis of Graves' disease.

1 May 2021 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
CCCintia E. Citterio
Cintia E. Citterio
CRCarina M. Rivolta
Carina M. Rivolta
HTHéctor Targovnik
Héctor Targovnik